Sort:
Open Access Review Issue
Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025
Cancer Innovation 2026, 5(2): e70059
Published: 16 April 2026
Abstract PDF (613.4 KB) Collect
Downloads:173

Hepatocellular carcinoma (HCC) remains a significant global health burden, characterized by high mortality and evolving etiological patterns marked by a rise in metabolic dysfunction‐associated cases. Over the past year, the therapeutic landscape has substantially evolved, driven by the maturity of clinical data regarding novel diagnostic and treatment strategies. This review synthesizes the milestone breakthroughs achieved through 2025 to provide an updated framework for the multidisciplinary management of this complex malignancy. Advances in early diagnosis have been propelled by the integration of artificial intelligence with imaging and the refinement of liquid biopsy biomarkers, significantly enhancing detection accuracy. Moreover, new findings on tumor microenvironment spatial ecosystem, metabolic reprogramming, and gut–liver axis are revealing new targets that shape these changing therapeutic modalities. Nowadays, in the clinical environment, the enhancement of resectability still gains momentum with novel conversion protocols and the least invasive approaches. One of the most notable changes is the latest development in perioperative care wherein combined systemic and locoregional interventions, such as combinations of immune checkpoint inhibitors and tyrosine kinase inhibitors, have attained previously unachieved pathological response and effectively decreased postoperative recurrence in high‐risk patients. In case of progressive disease, advances in treatment models of choice have put a strong emphasis on using combination systems of regimens, which have proven better survival advantages than conventional monotherapies. All these developments highlight the shift from mono‐modality therapies to more complex and individualized combination approaches, which imply that comprehensive multimodal interventions will become a standard of care and enhance patient outcomes in the long term among patients with HCC.

Open Access Review Issue
Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies
Cancer Biology & Medicine 2024, 21(10): 849-863
Published: 19 September 2024
Abstract PDF (906.6 KB) Collect
Downloads:69

Neutrophils, which originate from the bone marrow and are characterized by a segmented nucleus and a brief lifespan, have a crucial role in the body’s defense against infections and acute inflammation. Recent research has uncovered the complex roles of neutrophils as regulators in tumorigenesis, during which neutrophils exhibit a dualistic nature that promotes or inhibits tumor progression. This adaptability is pivotal within the tumor microenvironment (TME). In this review, we provide a comprehensive characterization of neutrophil plasticity and heterogeneity, aiming to illuminate current research findings and discuss potential therapeutic avenues. By delineating the intricate interplay of neutrophils in the TME, this review further underscores the urgent need to understand the dual functions of neutrophils with particular emphasis on the anti-tumor effects to facilitate the development of effective therapeutic strategies against cancer.

Open Access Review Issue
Artificial intelligence-based pathological analysis of liver cancer: Current advancements and interpretative strategies
iLIVER 2024, 3(1): 100082
Published: 08 February 2024
Abstract PDF (1.9 MB) Collect
Downloads:62

In recent years, significant advances have been achieved in liver cancer management with the development of artificial intelligence (AI). AI-based pathological analysis can extract crucial information from whole slide images to assist clinicians in all aspects from diagnosis to prognosis and molecular profiling. However, AI techniques have a “black box” nature, which means that interpretability is of utmost importance because it is key to ensuring the reliability of the methods and building trust among clinicians for actual clinical implementation. In this paper, we provide an overview of current technical advancements in the AI-based pathological analysis of liver cancer, and delve into the strategies used in recent studies to unravel the “black box” of AI's decision-making process.

Open Access Review Issue
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
Cancer Biology & Medicine 2023, 20(3): 181-195
Published: 24 March 2023
Abstract PDF (518.5 KB) Collect
Downloads:120

Advances in antibody engineering have led to the generation of more innovative antibody drugs, such as bispecific antibodies (bsAbs). Following the success associated with blinatumomab, bsAbs have attracted enormous interest in the field of cancer immunotherapy. By specifically targeting two different antigens, bsAbs reduce the distance between tumor and immune cells, thereby enhancing tumor killing directly. There are several mechanisms of action upon which bsAbs have been exploited. Accumulating experience on checkpoint-based therapy has promoted the clinical transformation of bsAbs targeting immunomodulatory checkpoints. Cadonilimab (PD-1 × CTLA-4) is the first approved bsAb targeting dual inhibitory checkpoints, which confirms the feasibility of bsAbs in immunotherapy. In this review we analyzed the mechanisms by which bsAbs targeting immunomodulatory checkpoints and their emerging applications in cancer immunotherapy.

Open Access Perspective Issue
Decoding the complexity of metastasis
Cancer Biology & Medicine 2022, 19(3): 284-288
Published: 15 March 2022
Abstract PDF (519.5 KB) Collect
Downloads:53
Total 5